贝那普利联合螺内酯治疗非腺瘤型原发性醛固酮增多症的疗效

Therapeutic effects of benazepril combined spironolactone on non-adenoma primary aldosteronism

目的:探讨贝那普利联合螺内酯治疗非腺瘤型原发性醛固酮增多症的疗效。方法:非腺瘤型原发性醛固酮增多症122例患者按数字表法被随机分为贝那普利组(61例,贝那普利联合螺内酯治疗)和硝苯地平组(61例,硝苯地平控释片联合螺内酯治疗)。检测治疗前及治疗12个月后两组患者血压、血清钾,血浆肌酐浓度,并进行比较。结果:治疗前两组患者血压、血清钾,血浆肌酐浓度均无显著差异(P均>0.05);治疗后,与硝苯地平组比较,贝那普利组舒张压[(95.19±7.22)mmHg比(89.82±10.20)mmHg]显著下降(P=0.001);血钾水平[(3.79±0.40)mmol/L比(4.02±0.37)mmol/L,P=0.001]明显升高,两组治疗后未引起血浆肌酐浓度明显的变化(P均>0.05)。结论:贝那普利联合螺内酯治疗非腺瘤型原发性醛固酮增多症能取得比硝苯地平更好的疗效,并且是安全的,值得推广应用。

Objective： To explore the therapeutic effects of benazepril combined spironolactone on non-adenoma pri- mary aldosteronism. Methods： A total of 122 patients with non-adenoma primary aldosteronism were randomly di- vided into benazepril group （n = 61, received benazepril combined spironolactone） and nifedipine group （n = 61, re- ceived nifedipine controlled release tablets combined spironolactone） according to number table method. Blood pressure, serum potassium and plasma creatinine concentration were measured and compared between two groups be- fore and 12 months after treatment. Results： Before treatment, there were no significant difference in blood pres- sure level, serum potassium level and plasma creatinine concentration between two groups （P^0.05 all） ; compared with nifedipine group after treatment, there was significant reduction in diastolic blood pressure [- （95.19 ± 7.22） mmHg vs. （89.82 ± 10.20） mmHg], P = 0. 001 ] there was significant rise in serum potassium level [- （3.79 ± 0.40） mmol/L vs. （4. 02 ± 0.37） mmol/L, P = 0. 001]. There wits no significant change in plasma creatinine concentra- tion in two groups after treatment, P〉0.05. Conclusion： Benazepril combined spironolactone treatment can achieve better therapeutic effects than that of nifedipine and it＇s safe ill patients with non-adenoma primary aldosteronism, which should be extended.